PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2123628
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2123628
According to Mordor Intelligence, fundus camera market size in 2026 is estimated at USD 512.54 million, growing from 2025 value of USD 486.97 million with 2031 projections showing USD 662.18 million, growing at 5.25% CAGR over 2026-2031.

This report is Segmented by Product Type (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and More), Modality (Hand-Held Devices, and More), Application (Diabetic Retinopathy, Glaucoma, and More), End-User (Hospitals, Specialty & Eye Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Many countries now require annual retinal exams for people with diabetes, and U.S. Medicare policies deem AI-interpreted fundus images medically necessary. These rules spur bulk purchases of cameras that produce AI-ready images and support telemedicine workflows. More than 4.1 million U.S. adults live with diabetic retinopathy, and systematic screening using fundus cameras prevents avoidable vision loss while lowering long-term care costs.
FDA-cleared AI platforms such as IDx-DR deliver >= 96% sensitivity and >= 93% specificity, producing results within three minutes of capture. Optos, Nikon and Google have co-developed ultra-widefield AI tools that detect macular edema alongside retinopathy. Clinicians value the speed, consistency and reduced dependence on specialist readers, making AI-enabled cameras an essential element of expanded screening programs.
Combination imaging platforms command premium pricing due to their sophisticated technology integration, with systems often exceeding USD 100,000 compared to standalone fundus cameras priced below USD 50,000. This cost differential becomes particularly challenging for specialty eye clinics and ambulatory surgical centers operating under tight budget constraints while seeking to offer comprehensive diagnostic capabilities. The economic pressure intensifies when considering ongoing maintenance costs, software licensing fees, and staff training requirements associated with complex imaging systems.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Non-mydriatic systems secured 47.62% share of the fundus camera market in 2025 thanks to painless, drop-free imaging that accelerates patient throughput. Their seamless EHR integration enables instant upload for AI review, supporting large screening programs. Zeiss's CIRRUS 6000 adds network-grade cybersecurity and the largest OCT reference database in the United States. Hybrid and wide-field devices are slated to expand at a 6.32% CAGR, capturing up to 200 degrees of retina in a single shot and doubling lesion detection rates.
Demand for ultra-widefield cameras grows in diabetic and peripheral-retinal disease management. Mydriatic cameras remain essential when maximum image clarity or research-grade color depth is required. Pediatric-specific cameras fill niche needs with tailored optics. The product palette thus enables providers to match imaging depth with clinical complexity while balancing capital budgets.
Hand-held devices held 53.10% of the fundus camera market share in 2025 as portability opened doors to rural clinics, emergency rooms and drive-through screenings. Smartphone-coupled models achieve comparable accuracy with lower acquisition cost. Combination platforms that merge OCT and fundus imaging will grow at a 7.02% CAGR, responding to clinics that want comprehensive data in one sitting.
Stationary table-top cameras remain common in high-volume centers that prioritize image consistency over mobility. Portable OCT units such as SightSync extend point-of-care diagnostics to community programs. User-friendly designs reduce technician training needs, supporting wider deployment across general-practice offices.
North America maintains market leadership with 41.20% share in 2025, supported by robust healthcare infrastructure, favorable reimbursement policies, and early adoption of AI-enabled diagnostic systems. The region benefits from comprehensive diabetic retinopathy screening programs and established telemedicine frameworks that facilitate fundus camera integration across diverse clinical settings. Major healthcare systems invest in advanced combination platforms that provide multimodal imaging capabilities, while rural areas increasingly adopt portable solutions to address geographic access barriers.
Asia-Pacific demonstrates the highest growth trajectory at 6.55% CAGR through 2031, driven by expanding healthcare access initiatives, rising diabetes prevalence, and government-backed screening programs across China, India, and Southeast Asian countries. The region's growth reflects substantial investments in healthcare infrastructure and increasing recognition of preventive eye care's economic benefits. Rural community-based eye care models emphasize portable fundus cameras and smartphone-based imaging solutions to overcome geographic and economic barriers that traditionally limited specialist access. Europe maintains steady growth supported by ESG-driven procurement policies that favor energy-efficient handheld devices and comprehensive regulatory frameworks that ensure device quality and safety standards.